- Conditions
- HPV-unrelated Head and Neck Squamous Cell Carcinoma
- Interventions
- Palbociclib, Cetuximab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 5
- States / cities
- Worthington, Minnesota • Kansas City, Missouri • St Louis, Missouri + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–322
of 322
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Cetuximab, Panitumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,010 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 5
- States / cities
- Stockton, California • Boynton Beach, Florida • Wichita, Kansas + 2 more
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Interventions
- Evorpacept (ALX148), Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- cetuximab, bevacizumab, gemcitabine
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • San Francisco, California • Stamford, Connecticut + 12 more
- Conditions
- Rectal Cancer
- Interventions
- Cetuximab, 5-fluorouracil, Pelvic irradiation
- Drug · Radiation
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Melbourne, Florida • Miami, Florida + 36 more
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine,, Cisplatin, Cetuximab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Stanford, California + 11 more
- Conditions
- Lung Cancer, Radiation Toxicity
- Interventions
- Cetuximab, Carboplatin, Paclitaxel, 60 Gy RT, 74 Gy RT
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 170 more
- Conditions
- Colorectal Cancer Metastatic, mCRC
- Interventions
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
- Biological · Drug · Procedure
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Head and Neck Neoplasms, Cancer of the Head and Neck
- Interventions
- Carboplatin, Cetuximab, RAD001
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Colorectal Cancer, Cancer of Pancreas, Pancreatic Neoplasm, Malignant Neoplasm of Large Intestine, Malignant Tumor of Colon, Colon Carcinoma, Cancer of Colon, Pancreatic Cancer
- Interventions
- FOLFOX6, EGFRBi armed ATC Infusions
- Drug · Biological
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan